Study Of Xuefuzhuyu Decoction On Treating Left Ventricular Diastolic Dysfunction Of Coronary Heart Disease

ObjectiveHeart failure is the end stage of cardiovascular diseases. Of all the diseases, coronary heart disease is the main cause of heart failure. Left ventricular diastolic dysfunction is one of the early performances of myocardial ischemia of coronary heart diseases. Reducing the left ventricular end-diastolic pressure and improving left ventricular compliance can prevent the further development from coronary heart disease to end-stage heart failure. This study was designed to investigate the clinical efficacy of Xuefuzhuyu decoction on treating left ventricular diastolic dysfunction with the syndrome of stagnation of qi and blood stasis. And observe the changes of left ventricular diastolic dysfunction parameters reacted on echocardiography, which is treated by Xuefuzhuyu decoction. We can provide better integrative treatment methods of treating left ventricular diastolic dysfunction in coronary heart disease patients from this study.MethodsThis study was a prospective randomized controlled one. Select 60 coronary heart disease patients which are diagnosed left ventricular diastolic dysfunction with the syndrome of stagnation of qi and blood stasis from Guangzhou Hospital of TCM. The 60 patients were grouped by randomized method, which were divided into treatment and control group, each group includes 30 people. The control group takes conventional single treatment of coronary heart disease. On the basis of control group drugs, the treatment group takes another Xuefuzhuyu decoction. Observe the clinical efficacy after treatment for 14 days. And compare the left ventricular diastolic dysfunction parameters (E, A, E/A) reacted on echocardiography before and after treatment in the two groups.Results1. The two groups have no statistical significance (P> 0.05) in gender, age,the left ventricular diastolic dysfunction parameters (E, A, E/ A), clinical syndrome scores, and the efficacy.2.2. Changes in left ventricular diastolic function:The treatment group has statistically significant difference in E, A and E/A (P<0.05) after the end of the course. The control group has no statistically significant difference in E, A before and after the end of the course. However, the control group has statistically significant difference in E (P<0.05) after the end of the course. There are significant differences in E, A and E/A (P<0.05), between the treatment group and the control group.3. Changes in clinical syndrome scores:The two groups have no statistically significant difference in clinical syndrome scores before and after the end of the course. The two groups have statistically significant difference in clinical syndrome scores (P<0.05) before and after the end of the course. And there are significant differences in clinical syndrome scores (P<0.05), between the treatment group and the control group.4. There are significant differences in clinical efficacy (P<0.05) between the treatment group and the control group.Conclusions1. Two groups of patients have no obvious difference in gender, and age. They can be compared.2. There are significant differences in E/A after treatment in the two groups, which indicates that the two groups both can improve the left ventricular diastolic function. After treatment, the treatment group is significant different from the control group in E、A、E/A, which indicates that the treatment group is superior to that of the control group.3. There are significant differences in clinical syndrome scores after the treatment in the two groups, which indicates that the two groups both can reduce the clinical syndrome scores. After treatment, the treatment group is significant different from the control group in clinical syndrome scores, which indicates that the treatment group is superior to that of the control group.4. After treatment, the treatment group is significant different from the control group in clinical efficacy, which indicates that the treatment group is superior to that of the control group.